Jaguar Health (NASDAQ:JAGX) Receives Buy Rating from HC Wainwright

Share on StockTwits

HC Wainwright reiterated their buy rating on shares of Jaguar Health (NASDAQ:JAGX) in a research note published on Monday morning, AnalystRatings.com reports. The firm currently has a $3.00 target price on the biotechnology company’s stock, down from their previous target price of $10.00.

Several other analysts also recently commented on the stock. LADENBURG THALM/SH SH started coverage on shares of Jaguar Health in a research report on Thursday, September 12th. They issued a buy rating and a $5.00 target price for the company. ValuEngine raised shares of Jaguar Health from a hold rating to a buy rating in a research report on Thursday, November 14th. Finally, Zacks Investment Research raised shares of Jaguar Health from a hold rating to a buy rating and set a $1.00 target price for the company in a research report on Thursday, November 14th.

Jaguar Health stock traded down $0.03 during trading hours on Monday, hitting $0.64. The company had a trading volume of 501,800 shares, compared to its average volume of 558,277. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.88 and a quick ratio of 0.61. The firm has a market capitalization of $30.67 million, a P/E ratio of 0.00 and a beta of 0.71. Jaguar Health has a fifty-two week low of $0.61 and a fifty-two week high of $36.39. The firm’s fifty day moving average is $0.81 and its 200-day moving average is $1.77.

A hedge fund recently bought a new stake in Jaguar Health stock. Wedbush Securities Inc. bought a new position in Jaguar Health Inc (NASDAQ:JAGX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 25,100 shares of the biotechnology company’s stock, valued at approximately $33,000. Wedbush Securities Inc. owned approximately 0.05% of Jaguar Health as of its most recent SEC filing. 0.11% of the stock is owned by institutional investors.

About Jaguar Health

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

See Also: Cash Asset Ratio

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bitcoin Private   Trading 4.7% Lower  This Week
Bitcoin Private Trading 4.7% Lower This Week
Joint Ventures  Trading 3.1% Higher  Over Last Week
Joint Ventures Trading 3.1% Higher Over Last Week
Bitradio 24-Hour Trading Volume Reaches $50.00
Bitradio 24-Hour Trading Volume Reaches $50.00
Aegeus Reaches Market Capitalization of $26,594.00
Aegeus Reaches Market Capitalization of $26,594.00
Extraction Oil & Gas Inc  Expected to Announce Earnings of -$0.07 Per Share
Extraction Oil & Gas Inc Expected to Announce Earnings of -$0.07 Per Share
$6.90 Million in Sales Expected for Cytosorbents Corp  This Quarter
$6.90 Million in Sales Expected for Cytosorbents Corp This Quarter


© 2006-2019 Ticker Report